Stockreport

Prelude Therapeutics Announces IND Clearance for PRT2527, a Highly Selective CDK9 Inhibitor

Prelude Therapeutics Incorporated  (PRLD) 
PDF WILMINGTON, Del., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that the Uni [Read more]